It seems that billionaire biotech investor Jim Mellon is the flavor of the month as he continues the drive to create a rejuvenation biotech industry. Jim and his colleagues at Juvenescence have announced that they have secured another $100M for the company, and it will be used to invest and support the growth of promising…

Today, we want to highlight an interview with billionaire investor Jim Mellon that our friend, Adam Ford of Science, Technology, and the Future, has conducted. Like us, Adam was at the Undoing Aging conference in Berlin earlier this year, and, just as we were, he was busy conducting a number of interviews with the researchers…

I recently visited the Longevity Leaders Conference in London and had the opportunity to speak with Kelsey Moody, the CEO of Ichor Therapeutics, a company focused on targeting age-related diseases by targeting the aging processes themselves. I previously interviewed him back in 2017, so it was the ideal time to catch up on what had…

Yet another important investment in the field of regenerative medicine against aging demonstrates the increasing interest of investors in this industry; on August 2, BioTime, Inc. announced that Juvenescence Limited will buy 14.4 million of its subsidiary AgeX Therapeutics‘ shares for a total of $43.2 million—50% to be paid in cash and 50% with a…

July is here, and our upcoming conference in New York City is only a handful of days away! If you haven’t done so already, go and get your ticket now so that you can enjoy the June roundup fully relaxed, knowing that your seat is secured. About our NYC conference On the off chance you’ve…

We were interested to learn that Juvenescence Limited, a biotech and development company involved in the development of therapies that target the aging processes, has successfully raised $50 million in a series A financing round. Jim Mellon, the chairman of Juvenescence Limited, said, “We are delighted with the progress we have made and the faith…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD